Tomas J. Heyman - 15 Sep 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
15 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 16:15:12 UTC
Previous filing
24 Jun 2022
Next filing
25 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +26,400 $0.000000 26,400 15 Sep 2022 Common Stock 26,400 $3.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on September 15, 2022 and will vest in three equal installments on September 15, 2023, September 15, 2024 and September 15, 2025, subject to the Reporting Person's continued service as a director of the Issuer through the applicable vesting date.